A survival method to estimate the time to occurrence of mutations: An application to thymidine analogue mutations in HIV-1-infected patients

Journal of Infectious Diseases

Volumn 189, Issue 5, 2004, Pages 862-870

  Flandre, Philippe ^a   Descamps, Diane ^b   Joly, Véronique ^b   Meiffrédy, Vincent ^a   Tamalet, Catherine ^c   Izopet, Jacques ^d   Brun Vézinet, Françoise ^b  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c TIMONE HOSPITAL   (France)

^d CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL; VIRUS GENOME; VIRUS MUTATION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ALGORITHMS; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; GENOME, VIRAL; GENOTYPE; HIV-1; HUMANS; IMMUNITY, NATURAL; LIKELIHOOD FUNCTIONS; MUTATION; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; THYMIDINE; TIME FACTORS;

EID: 1542267693     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/381676     Document Type: Article

References (24)

1. Boucher CA, O'Suilivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165:105-10.
2. Nielsen C, Bruun L, Mathielsen LR, Pedersen C, Gerstoft J. Development of resistance to zidovudine (ZDV) and didanosine (ddl) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy. AIDS 1996; 10:625-33.
3. Brun-Vezinet F, Boucher CAB, Loveday C, et al. HIV-1 viral load phenotype and resistance in a subset of drug naive participants from the DELTA trial. Lancet 1997; 350:983-90.
4. Pellegrin I, Izopet I, Reynes J, et al. Emergence of zidovudine and multidrug-resistance mutations in HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. AIDS 1999; 13:1705-9.
5. Hanna GJ, Johnson VA, Kuritzkes DR, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000; 181:904-11.
6. Kuritzkes DR, Shugarts D, Bakhtiari M, et al. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. J Acquir Immune Defic Syndr 2000; 23:26-34.
7. Kuritzkes DR, Sevin A, Young B, et al. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine- ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group Protocol 315. J Infect Dis 2000; 181:491-7.
8. Shulman NS, Machekano RA, Shafer RW, et al. Genotypic corrrelates of a virologic response to stavudine after zidovudine monotherapy. J Acquir Immune Defic Syndr 2001; 27:377-80.
9. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002; 16:1331-40.
10. Descamps D, Flandre P, Joly V, et al. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir. J Acquir Immune Defic Syndr 2002; 31:464-71.
11. Joly V, Flandre P, Meiffredy V, et al. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside experienced patients with prior exposure to lamivudine, stavudine or protease inhibitors (Novavir trial). Antimicrob Agents Chemother 2002; 46:1906-13.
12. Pasquier C, Millot N, Njoum R, et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods 2001; 94:45-54.
13. Turnbull B. The empirical distribution function with arbitrarily grouped, censored and truncated data. J R Stat Soc Ser B 1976; 38: 290-95.
14. Frydman H. A note on nonparametric estimation of the distribution function from interval-censored and truncated observations. J R Stat Soc Ser B 1994; 56:71-74.
15. Lindsey JC, Ryan LM. Tutorial in biostatistics methods for interval-censored data. Stat Med 1998; 17:219-38.
16. Flandre P, Descamps D, Joly V, et al. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to the initial regimen received. Antivir Ther 2003; 8:65-72.
17. Sun J. A non-parametric test for interval-censored failure time data with application to AIDS studies. Stat Med 1996; 15:1387-95.
18. Descamps D, Masquelier B, Leport C, et al. Detection of resistance mutations in patients receiving a first line proteases inhibitor containing regimen with undetectable plasma viral load [abstract 139]. In: Abstracts of the XI International HIV Drug Resistance Workshop: basic principles and clinical implications (Seville, Spain). Antivir Ther 2002(Suppl 1):S115.
19. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000; 283:205-11.
20. Flandre P, Raffi F, Descamps D, et al. Final analysis of the TRILEGE induction-maintenance trial: results at 18 months. AIDS 2002; 16: 561-68.
21. Richman D. Susceptibility to nucleoside analogues of zidovudine- resistant isolates of human immunodeficiency virus. Am J Med 1990; 88:8S-10S.
22. Marcelin A, Wirden M, Delaugerre C, et al. Selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors occurs step by step and through two different pathways [abstract 7]. In: Abstracts of the XI International HIV Drug Resistance Workshop: basic principles and clinical implications (Seville, Spain). Antivir Ther 2002 (Suppl 1):S34.
23. Miller M, Margot N, Lu B. Effect of baseline nucleoside-associated resistance on response to tenofovir DF therapy: integrated analyses of studies 902 and 907 [abstract 43]. In: 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
24. Masquelier B, Tamalet C, Descamps D, et al. Identification of genotypic determinants of the virological response to tenofovir-including regimens in nucleoside reverse transcriptase inhibitor experienced patients. In: Abstracts of the XI International HIV Drug Resistance Workshop: basic principles and clinical implications (Seville, Spain). Antivir Ther 2002(Suppl 1):S105.